Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00971204 · ClinicalTrials.gov registry record · Phase 2
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
A Phase 2 study of Paroxysmal Atrial Fibrillation, sponsored by CardioFocus.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 10
- Study locations
NCT00971204 is a Phase 2 study of Paroxysmal Atrial Fibrillation that has completed, run by CardioFocus. The registered enrollment target is 100 participants, below the 855-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00971204, a Phase 2 study of Paroxysmal Atrial Fibrillation, has completed, sponsored by CardioFocus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a demonstration of safety and efficacy of the ablation for pulmonary vein isolation in the treatment of paroxysmal atrial fibrillation.
Conditions Studied
Interventions
- DEVICE CardioFocus HeartLight Endoscopic Ablation System
Study Locations (10)
Texas
- Texas Cardiac Arrhythmia Research Foundation - Austin
- The Methodist Hospital Research Institute - Houston
Virginia
- University Of Virginia Health System - Charlottesville
- Sentara Norfolk General Hospital - Norfolk
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Pacific Heart Institute - Santa Monica
Michigan
- William Beaumont Hospital - Royal Oak
New York
- Mt. Sinai Hospital - New York
Pennsylvania
- University of Pennsylvania Health System - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00971204
The ClinicalTrials.gov registry entry for NCT00971204 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 855-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (88% lower). The listed sponsor is CardioFocus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CardioFocus HeartLight Endoscopic Ablation System is the first listed.
NCT00971204 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Texas, Virginia, Alabama.
Frequently Asked Questions
What is clinical trial NCT00971204 about?
NCT00971204 is a clinical study titled "Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation". This is a demonstration of safety and efficacy of the ablation for pulmonary vein isolation in the treatment of paroxysmal atrial fibrillation.
What is the current status of trial NCT00971204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2009-09. Estimated completion is 2012-06.
What conditions does trial NCT00971204 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT00971204?
The interventions under investigation include: CardioFocus HeartLight Endoscopic Ablation System (DEVICE).
Who is sponsoring clinical trial NCT00971204?
This trial is sponsored by CardioFocus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00971204 being conducted?
This trial has 10 study locations across Alabama, California, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
STOP AF First Post-Approval Study
RECRUITING
-
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
RECRUITING
-
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
RECRUITING
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.